Kanaph Therapeutics is a biotech with activities that range from drug discovery to early stage clinical trials. We are dedicated to developing next generation therapeutics for oncology and autoimmune diseases. Our oncology pipeline includes bi-specific antibodies and small molecules that have a greatly enhanced immuno-stimulatory activity in the tumor micro-environment (TME) for efficient tumor eradication. Our autoimmune disease pipeline is composed of bispecific Fc-fusions that inhibit the alternative complement pathway while inhibiting angiogenesis and downstream complement activation as well.

Founded and headquartered in Seoul, we have recruited and will continue to recruit a diverse yet experienced pool of scientists with drug development experience across Korea and the US. By harnessing and integrating their expertise, we aim to create new ideas and synergies that will be translated into the development of new therapies.